ATYR PHARMA

aTyr's mission is to translate findings from our tRNA synthetase platform into new therapeutics for fibrosis, inflammation and cancer... Efzofitimod is a first-in-class biologic based on a naturally occurring, lung-enriched splice variant of histidyl-tRNA synthetase (HARS) that downregulates immune responses via selective modulation of neuropilin-2 (NRP2). We are developing efzofitimod as a potential disease-modifying therapy for patients with interstitial lung disease (ILD), a group of rare immune-mediated disorders that can cause progressive fibrosis of the lung. Our lead indication for efzofitimod is pulmonary sarcoidosis, the most prevalent form of ILD. We are currently investigating efzofitimod in patients with pulmonary sarcoidosis in a global Phase 3 study known as EFZO-FIT™... In addition to efzofitimod, we have a pipeline of therapeutic candidates derived from our proprietary tRNA synthetase platform.

Also known as: aTyr Pharma Inc.

Primary location: San Diego United States